RS54199B1 - Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora - Google Patents

Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora

Info

Publication number
RS54199B1
RS54199B1 RS20150204A RSP20150204A RS54199B1 RS 54199 B1 RS54199 B1 RS 54199B1 RS 20150204 A RS20150204 A RS 20150204A RS P20150204 A RSP20150204 A RS P20150204A RS 54199 B1 RS54199 B1 RS 54199B1
Authority
RS
Serbia
Prior art keywords
fluid
cartridge
trigger
gear
bottle
Prior art date
Application number
RS20150204A
Other languages
English (en)
Serbian (sr)
Inventor
Chaozhong Cai
Wei He
Robert W. Kavash
Henry J. Breslin
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34962827&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS54199(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of RS54199B1 publication Critical patent/RS54199B1/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/04—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D275/06—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings condensed with carbocyclic rings or ring systems with hetero atoms directly attached to the ring sulfur atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Amplitude Modulation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Eye Examination Apparatus (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Amplifiers (AREA)
RS20150204A 2004-03-15 2005-03-14 Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora RS54199B1 (sr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55334204P 2004-03-15 2004-03-15

Publications (1)

Publication Number Publication Date
RS54199B1 true RS54199B1 (sr) 2015-12-31

Family

ID=34962827

Family Applications (4)

Application Number Title Priority Date Filing Date
RS20150204A RS54199B1 (sr) 2004-03-15 2005-03-14 Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora
RS20160843A RS55122B1 (sr) 2004-03-15 2005-03-14 Modulatori opioidnih receptora
RS20110446A RS51995B (sr) 2004-03-15 2005-03-14 Nova jedinjenja kao modulatori opioidnog receptora
RS20130371A RS52933B (sr) 2004-03-15 2005-03-14 Modulatori opioidnog receptora

Family Applications After (3)

Application Number Title Priority Date Filing Date
RS20160843A RS55122B1 (sr) 2004-03-15 2005-03-14 Modulatori opioidnih receptora
RS20110446A RS51995B (sr) 2004-03-15 2005-03-14 Nova jedinjenja kao modulatori opioidnog receptora
RS20130371A RS52933B (sr) 2004-03-15 2005-03-14 Modulatori opioidnog receptora

Country Status (35)

Country Link
US (8) US7741356B2 (enExample)
EP (5) EP2298744B1 (enExample)
JP (1) JP4778954B2 (enExample)
KR (1) KR101166342B1 (enExample)
CN (2) CN102786476B (enExample)
AR (2) AR048269A1 (enExample)
AT (1) ATE516274T1 (enExample)
AU (1) AU2005224091B2 (enExample)
BR (1) BRPI0508820B8 (enExample)
CA (1) CA2560047C (enExample)
CR (1) CR8655A (enExample)
CY (3) CY1111927T1 (enExample)
DK (5) DK3112352T3 (enExample)
EC (1) ECSP066856A (enExample)
ES (5) ES2367576T3 (enExample)
HR (4) HRP20110694T1 (enExample)
HU (2) HUE029852T2 (enExample)
IL (3) IL178040A (enExample)
LT (2) LT2653465T (enExample)
LU (1) LUC00007I2 (enExample)
ME (3) ME02221B (enExample)
MX (1) MXPA06010642A (enExample)
MY (1) MY146972A (enExample)
NL (1) NL300865I2 (enExample)
NO (3) NO338203B1 (enExample)
NZ (1) NZ549842A (enExample)
PH (1) PH12012501640B1 (enExample)
PL (4) PL2573068T3 (enExample)
PT (4) PT2653465T (enExample)
RS (4) RS54199B1 (enExample)
SI (4) SI2573068T1 (enExample)
TW (1) TWI361069B (enExample)
UA (1) UA86053C2 (enExample)
WO (1) WO2005090315A1 (enExample)
ZA (1) ZA200608587B (enExample)

Families Citing this family (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI239847B (en) 1997-12-02 2005-09-21 Elan Pharm Inc N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease
US20080050367A1 (en) 1998-04-07 2008-02-28 Guriq Basi Humanized antibodies that recognize beta amyloid peptide
RS54199B1 (sr) * 2004-03-15 2015-12-31 Janssen Pharmaceutica Nv Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora
NZ551288A (en) 2004-05-14 2010-10-29 Janssen Pharmaceutica Nv Carboxamido opioid compounds that are derivatives of tramadol
TW200635607A (en) 2004-12-15 2006-10-16 Elan Pharm Inc Humanized Aβ antibodies for use in improving cognition
EA014366B1 (ru) * 2005-03-14 2010-10-29 Янссен Фармацевтика, Н.В. Способ получения опиоидных модуляторов
EA014245B1 (ru) * 2005-12-14 2010-10-29 Бристол-Маерс Сквибб Компани Аналоги арилпропионамида, арилакриламида, арилпропинамида или арилметилмочевины в качестве ингибиторов фактора xia
CN101336229B (zh) 2005-12-23 2012-06-13 西兰岛药物有限公司 改性的拟赖氨酸化合物
AU2007237096C1 (en) 2006-04-07 2012-12-13 EyePoint Pharmaceuticals, Inc. Antibodies that bind human protein tyrosine phosphatase beta (HPTPbeta) and uses thereof
US8784810B2 (en) 2006-04-18 2014-07-22 Janssen Alzheimer Immunotherapy Treatment of amyloidogenic diseases
US7622593B2 (en) 2006-06-27 2009-11-24 The Procter & Gamble Company Human protein tyrosine phosphatase inhibitors and methods of use
US20080188545A1 (en) 2006-12-21 2008-08-07 Alimardanov Asaf R Synthesis of pyrrolidine compounds
EP2176234B1 (en) 2007-07-09 2016-01-27 Forest Tosara Limited Novel crystals and process of making 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy- benzoic acid
DK2182983T3 (da) 2007-07-27 2014-07-14 Janssen Alzheimer Immunotherap Behandling af amyloidogene sygdomme med humaniserede anti-abeta antistoffer
JO3076B1 (ar) 2007-10-17 2017-03-15 Janssen Alzheimer Immunotherap نظم العلاج المناعي المعتمد على حالة apoe
TWI468375B (zh) * 2008-10-27 2015-01-11 Janssen Pharmaceutica Nv 製備經保護之ｌ－丙胺酸衍生物之方法
US9067981B1 (en) 2008-10-30 2015-06-30 Janssen Sciences Ireland Uc Hybrid amyloid-beta antibodies
JP5198220B2 (ja) * 2008-11-13 2013-05-15 東ソ−・エフテック株式会社 アミノ酸誘導体の製造方法
CA2748765C (en) 2009-07-06 2014-07-22 Akebia Therapeutics Inc. Compounds, compositions, and methods for preventing metastasis of cancer cells
CA2836311A1 (en) 2011-05-16 2012-11-22 Bionomics Limited Amine derivatives as potassium channel blockers
EP2524912A1 (en) 2011-05-16 2012-11-21 Bionomics Limited Amine derivatives
EP3505182A1 (en) 2011-10-13 2019-07-03 Aerpio Therapeutics, Inc. Methods for treating vascular leak syndrome and cancer
US9120757B2 (en) 2013-03-14 2015-09-01 Epizyme, Inc. Arginine methyltransferase inhibitors and uses thereof
EP2970135B1 (en) 2013-03-14 2018-07-18 Epizyme, Inc. Pyrazole derivatives as prmt1 inhibitors and uses thereof
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations
US9447079B2 (en) * 2013-03-14 2016-09-20 Epizyme, Inc. PRMT1 inhibitors and uses thereof
SI2970132T1 (sl) 2013-03-14 2021-02-26 Epizyme, Inc. Inhibitorji argininmetiltransferaze in njihove uporabe
US20150050277A1 (en) 2013-03-15 2015-02-19 Aerpio Therapeutics Inc. Compositions and methods for treating ocular diseases
CN106456614A (zh) 2014-03-14 2017-02-22 爱尔皮奥治疗有限公司 HPTP‑β抑制剂
IS2977B (is) 2015-02-23 2017-07-15 Actavis Group Ptc Ehf. Aðferð til framleiðslu á milliefnum sem eru nytsamleg við nýsmíði á elúxadólíni
EP3319444B1 (en) 2015-07-09 2022-03-09 The Regents of the University of California Mu opioid receptor modulators
EP3325450A1 (en) 2015-07-23 2018-05-30 Teva Pharmaceuticals International GmbH Solid state forms of eluxadoline
JPWO2017043626A1 (ja) * 2015-09-11 2018-06-21 株式会社カネカ 光学活性４−カルバモイル−２，６−ジメチルフェニルアラニン誘導体の製造法
MX387804B (es) 2015-09-23 2025-03-19 Aerpio Therapeutics Inc Metodos para tratar presion intraocular con activadores de tie-2
CN105250232B (zh) * 2015-09-29 2018-08-14 江苏汇智知识产权服务有限公司 一种伊卢多啉肠溶片及其制备方法
WO2017114446A1 (zh) * 2015-12-31 2017-07-06 苏州晶云药物科技有限公司 艾沙度林的新晶型及其制备方法
EP3272741A1 (en) 2016-07-21 2018-01-24 Euticals S.P.A. New stable solvate crystalline forms of eluxadoline
CN105777584B (zh) * 2016-03-28 2018-01-02 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
CN105693554B (zh) * 2016-04-06 2017-08-08 成都伊诺达博医药科技有限公司 丙氨酸衍生物的制备方法
US20190177281A1 (en) * 2016-05-03 2019-06-13 Sromovasam THIRUMALAI RAJAN Process for the preparation of 5-[[[(2s)-2-amino-3-[4-(aminocarbonyl)-2,6-dimethylphenyl]-1-oxopropyl] [(1s)-1-(4-phenyl-1h-imidazol-2-yl)ethyl]amino] methyl-2-methoxybenzoic acid and its polymorphs thereof
MA45184A (fr) * 2016-05-30 2019-04-10 Sun Pharmaceutical Ind Ltd Procédé de préparation de l'éluxadoline .
EP3474847B1 (en) * 2016-06-23 2022-09-07 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018020450A2 (en) 2016-07-28 2018-02-01 Lupin Limited Process for the preparation of eluxadoline
CZ2016548A3 (cs) 2016-09-07 2018-03-14 Zentiva, K.S. Pevné formy eluxadolinu
WO2018047131A1 (en) * 2016-09-09 2018-03-15 Sun Pharmaceutical Industries Limited Amorphous eluxadoline
US10479769B2 (en) 2016-09-20 2019-11-19 Sun Pharmaceutical Industries Limited Processes for the preparation of eluxadoline
WO2018138272A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline form and process for the preparation thereof
WO2018138274A1 (en) 2017-01-27 2018-08-02 Quimica Sintetica, S. A. Eluxadoline crystalline forms and processes for their preparation
US11324799B2 (en) 2017-05-05 2022-05-10 Zealand Pharma A/S Gap junction intercellular communication modulators and their use for the treatment of diabetic eye disease
WO2019008604A1 (en) 2017-07-07 2019-01-10 Cipla Limited NEW FORMS OF MU-OPIOID RECEPTOR AGONIST
WO2019144805A1 (zh) * 2018-01-25 2019-08-01 四川科伦博泰生物医药股份有限公司 取代的苯乙胺化合物及其制备方法和用途
WO2019197274A1 (en) 2018-04-09 2019-10-17 Quimica Sintetica, S. A. Process for the preparation of opioid modulators
CA3109557A1 (en) 2018-08-20 2020-02-27 Allergan Holdings Unlimited Company Polymorphs of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
EP3856245A4 (en) 2018-09-24 2022-10-26 EyePoint Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - ß (VE-PTP) AND VEGF
DK3659433T3 (da) * 2018-11-30 2021-04-19 Phytobiotics Futterzusatzstoffe Gmbh System til analyse af billeder af dyrs afføring
CN111377832A (zh) * 2018-12-27 2020-07-07 江苏联昇化学有限公司 一种伊卢多啉中间体制备的新方法
JP7564824B2 (ja) 2019-04-29 2024-10-09 アイポイント ファーマシューティカルズ， インコーポレイテッド シュレム管を標的とするＴｉｅ－２活性化物質
WO2021198780A1 (en) 2020-03-30 2021-10-07 Allergan Holdings Unlimited Company Forms of 5-({[2-amino-3-(4-carbamoyl-2,6-dimethyl-phenyl)-propionyl]-[1-(4-phenyl-1h-imidazol-2-yl)-ethyl]-amino}-methyl)-2-methoxy-benzoic acid
MX2023001274A (es) * 2020-07-28 2023-04-24 Jazz Pharmaceuticals Ireland Ltd Sintesis quiral de inhibidores de raf biciclicos fusionados.
US11850319B2 (en) 2020-09-29 2023-12-26 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
US11896728B2 (en) 2020-09-29 2024-02-13 Abl Ip Holding Llc Techniques for directing ultraviolet energy towards a moving surface
CN114163348A (zh) * 2020-11-27 2022-03-11 成都泰蓉生物科技有限公司 一种氨酰基取代的l-苯丙氨酸的合成方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD142804A3 (de) * 1977-11-07 1980-07-16 Wagner Guenter Verfahren zur herstellung von na-alkyl-bzw.na-aryl-sulfonylierten omega-amidinophenyl-alpha-aminoalkylcarbonsaeureamiden
US4879398A (en) * 1987-12-31 1989-11-07 Monsanto Company Process for producing 2,6-disubstituted tyrosine
SE9402880D0 (sv) 1994-08-30 1994-08-30 Astra Ab New peptide derivatives
WO1996022997A1 (en) * 1995-01-27 1996-08-01 Novo Nordisk A/S Compounds with growth hormone releasing properties
US5565568A (en) 1995-04-06 1996-10-15 Eli Lilly And Company 2-acylaminopropanamides as tachykinin receptor antagonists
JP3950170B2 (ja) 1995-04-13 2007-07-25 アベンティス・ファーマスーティカルズ・インコーポレイテッド タキキニン受容体アンタゴニスト活性を有する新規な置換されたピペラジン誘導体
CA2203428A1 (en) 1995-08-21 1997-02-27 Philip Arthur Hipskind 2-acylaminopropanamides as growth hormone secretagogues
AU7710596A (en) 1995-11-29 1997-06-19 Nihon Nohyaku Co., Ltd. Phenylalanine derivatives, optically active substances, salts or coordination compounds thereof, and their use as fungicides
US5792760A (en) 1997-04-23 1998-08-11 Eli Lilly And Company Bisindoles as tachykinin receptor antagonists
IT1304898B1 (it) 1998-09-08 2001-04-05 Menarini Ricerche Spa Prodotti con caratteristiche basiche aventi attivita' antagonista sulrecettore nk-1 e loro impiego in preparazioni farmaceutiche
ES2206139T3 (es) * 1999-05-28 2004-05-16 Pfizer Products Inc. Derivados de 3-(3-hidrofenil)-3-amino-propionamida.
FR2796643B1 (fr) 1999-07-22 2005-04-29 Sod Conseils Rech Applic Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique
GB0021419D0 (en) 2000-08-31 2000-10-18 Oxford Glycosciences Uk Ltd Compounds
US20020072017A1 (en) * 2000-10-19 2002-06-13 Hudnall Phillip Montgomery Stabilized p-phenylenediamine-type photographic color developers in free base form
HU230376B1 (hu) 2000-10-30 2016-03-29 Janssen Pharmaceutica N.V Tripeptidil peptidáz inhibitorok
AU2002346994B2 (en) * 2001-10-15 2007-09-06 Janssen Pharmaceutica N.V. Novel substituted 4-phenyl-4-[1H-imidazol-2-yl]-piperidine derivatives and their use as selective non-peptide delta opioid agonists
US7041681B2 (en) 2002-04-29 2006-05-09 Janssen Pharmaceutica N.V. Compounds as opioid receptor modulators
RS54199B1 (sr) * 2004-03-15 2015-12-31 Janssen Pharmaceutica Nv Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora
CN1980917B (zh) * 2004-05-03 2014-02-12 詹森药业有限公司 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物
EA014366B1 (ru) * 2005-03-14 2010-10-29 Янссен Фармацевтика, Н.В. Способ получения опиоидных модуляторов

Also Published As

Publication number Publication date
US20160030393A1 (en) 2016-02-04
EP2573068B1 (en) 2014-12-31
ME02540B (me) 2017-02-20
US20140039024A1 (en) 2014-02-06
PT2653465T (pt) 2016-09-22
CN102786476A (zh) 2012-11-21
CN1950342A (zh) 2007-04-18
EP3112352A1 (en) 2017-01-04
ES2596434T3 (es) 2017-01-09
NL300865I2 (nl) 2020-08-17
AU2005224091A1 (en) 2005-09-29
PT1725537E (pt) 2011-09-08
US8772325B2 (en) 2014-07-08
CY1111927T1 (el) 2015-11-04
HK1155726A1 (en) 2012-05-25
PL2298744T3 (pl) 2013-11-29
EP1725537B1 (en) 2011-07-13
PT2573068E (pt) 2015-04-27
LUC00007I2 (enExample) 2017-05-02
US8609709B2 (en) 2013-12-17
CR8655A (es) 2008-09-09
ME01601B (me) 2014-09-20
BRPI0508820B1 (pt) 2018-04-10
IL229444A (en) 2017-03-30
AR095848A2 (es) 2015-11-18
KR20060131983A (ko) 2006-12-20
CA2560047C (en) 2013-12-24
AU2005224091B2 (en) 2012-02-02
IL178040A (en) 2013-12-31
HUS1700010I1 (hu) 2017-03-28
HK1099016A1 (en) 2007-08-03
MY146972A (en) 2012-10-15
PT2298744E (pt) 2013-09-12
US20100324051A1 (en) 2010-12-23
SI1725537T1 (sl) 2011-11-30
US7786158B2 (en) 2010-08-31
ES2367576T3 (es) 2011-11-04
NL300865I1 (nl) 2017-03-14
NO338203B1 (no) 2016-08-08
HUE029852T2 (en) 2017-04-28
US7741356B2 (en) 2010-06-22
PL2573068T3 (pl) 2015-06-30
TWI361069B (en) 2012-04-01
US20080096888A1 (en) 2008-04-24
EP2573068A1 (en) 2013-03-27
HRP20161331T1 (hr) 2016-12-30
HK1184432A1 (en) 2014-01-24
HRP20130800T1 (en) 2013-09-30
TW200539876A (en) 2005-12-16
LTPA2017005I1 (lt) 2017-03-27
LTC1725537I2 (lt) 2018-02-26
PL2653465T3 (pl) 2017-01-31
DK2573068T3 (en) 2015-02-16
MXPA06010642A (es) 2007-03-26
US20180325870A1 (en) 2018-11-15
NO20160916A1 (no) 2006-12-14
ECSP066856A (es) 2006-11-24
AR048269A1 (es) 2006-04-12
RS55122B1 (sr) 2016-12-30
PL1725537T3 (pl) 2011-12-30
ES2705077T3 (es) 2019-03-21
CY2017008I2 (el) 2017-11-14
WO2005090315A1 (en) 2005-09-29
RS51995B (sr) 2012-04-30
BRPI0508820A (pt) 2007-08-07
NZ549842A (en) 2010-10-29
ME02221B (me) 2016-02-20
EP2298744B1 (en) 2013-06-26
EP1725537A1 (en) 2006-11-29
PH12012501640A1 (en) 2015-10-05
CY2017008I1 (el) 2017-11-14
ZA200608587B (en) 2008-06-25
US9205076B2 (en) 2015-12-08
CN1950342B (zh) 2012-09-26
US20140256779A1 (en) 2014-09-11
CA2560047A1 (en) 2005-09-29
LUC00007I1 (enExample) 2017-03-03
KR101166342B1 (ko) 2012-07-18
EP2653465A1 (en) 2013-10-23
HRP20150305T1 (hr) 2015-04-24
CN102786476B (zh) 2017-01-18
SI2653465T1 (sl) 2016-10-28
LT2653465T (lt) 2016-09-12
US20130090478A1 (en) 2013-04-11
JP4778954B2 (ja) 2011-09-21
SI2573068T1 (sl) 2015-03-31
ATE516274T1 (de) 2011-07-15
EP2298744A3 (en) 2011-08-10
HK1105967A1 (en) 2008-02-29
ES2428008T3 (es) 2013-11-05
EP2573068B9 (en) 2015-08-26
JP2007529527A (ja) 2007-10-25
NO20064660L (no) 2006-12-14
HRP20110694T1 (hr) 2011-12-31
IL178040A0 (en) 2006-12-31
UA86053C2 (ru) 2009-03-25
NO2017007I2 (no) 2017-02-23
DK1725537T3 (da) 2011-10-31
IL229444A0 (en) 2013-12-31
DK3112352T3 (en) 2019-01-28
BRPI0508820B8 (pt) 2022-11-29
US8344011B2 (en) 2013-01-01
NO2017007I1 (no) 2017-02-23
RS52933B (sr) 2014-02-28
US20050203143A1 (en) 2005-09-15
PH12012501640B1 (en) 2015-10-05
EP2298744A2 (en) 2011-03-23
US10213415B2 (en) 2019-02-26
US9700542B2 (en) 2017-07-11
EP2653465B1 (en) 2016-07-13
CY1118096T1 (el) 2017-06-28
EP3112352B1 (en) 2018-11-21
SI2298744T1 (sl) 2013-10-30
DK2298744T3 (da) 2013-09-02
DK2653465T3 (da) 2016-08-22
ES2533176T3 (es) 2015-04-08
IL224908A (en) 2015-07-30

Similar Documents

Publication Publication Date Title
RS54199B1 (sr) Postupak za dobijanje intermedijera jedinjenja korisnih kao modulatori opioidnih receptora
US5881955A (en) Spraying device
US8235310B2 (en) Spraying device with interchangeable cartridge
US5320288A (en) Hose-end spraying apparatus
US4527740A (en) Hose-end aspirator sprayer
US4406406A (en) Liquid metering and dispensing apparatus
US5213264A (en) Spraying device with a replaceable cartridge
AU2009291952B2 (en) Sprayer
US6969010B1 (en) Landscape and agricultural sprayer foam marking attachment
US20250242368A1 (en) Hose end sprayer for wet or dry chemicals
WO2025110970A1 (en) Proportional liquid chemical injection device
MXPA99009552A (en) An improved spraying device
JPH0670573U (ja) 除草剤等の散布器